Roche (OTCMKTS:RHHBY) Rating Increased to Strong-Buy at Sanford C. Bernstein

Roche (OTCMKTS:RHHBY) was upgraded by equities researchers at Sanford C. Bernstein to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Roche Trading Down 1.5 %

Shares of OTCMKTS:RHHBY opened at $39.25 on Thursday. Roche has a one year low of $29.20 and a one year high of $42.43. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86. The company has a 50 day moving average of $36.14 and a 200-day moving average of $38.25.

Institutional Investors Weigh In On Roche

Several large investors have recently bought and sold shares of the company. Bard Financial Services Inc. lifted its stake in Roche by 37.7% in the fourth quarter. Bard Financial Services Inc. now owns 110,850 shares of the company’s stock valued at $3,866,000 after buying an additional 30,350 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Roche by 57.7% in the 3rd quarter. GAMMA Investing LLC now owns 7,944 shares of the company’s stock valued at $317,000 after acquiring an additional 2,906 shares during the period. Diversified Trust Co raised its stake in Roche by 6.4% in the third quarter. Diversified Trust Co now owns 59,742 shares of the company’s stock valued at $2,396,000 after buying an additional 3,613 shares during the period. Canopy Partners LLC boosted its position in Roche by 4.6% during the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after purchasing an additional 344 shares during the period. Finally, Verity Asset Management Inc. acquired a new position in Roche in the 3rd quarter valued at about $253,000.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.